P-458 - Therapeutically strategies and outcome in mild cognitive impairment - 13/06/12
Résumé |
Introduction |
Mild cognitive impairment(MCI) is considered to be a potential transitional stage between normal cognitive function and dementia.
Objective |
To determine comparatively the outcome of patients treated with different therapies.
Methods |
There were included 193 subjects with MCI, aged over 65. They were evaluated after 6 months, 1 year and 2 years of treatment using Mini Mental State Examination (MMSE) and clock test.
• | Group A -43 patients treated with piracetamum(daily dose:1600mg). |
• | Group B that comprises 44 patients diagnosed with MCI treated with rhodiola rosea, 2 capsules/day. |
• | Group C -41 patients which were treated with antioxidant agents(vitaminE 800ui/day). |
• | Group D -36 subjects treated with piracetamum associated with rhodiola rosea and vitamin E. |
• | Group E -29 patients without treatment. |
Results |
Mean of MMSE score at inclusion was 24,49 (SD=2,1). After 6 months of treatment MMSE score improve in groups treated with 1,35 points in group A, 1,41 for group B, 1,12 points for group C, 1,18 points in group D and in group E we observed an impairment with 0,52 points. In groups A, B, C and D after 1 year of treatment the improvement is with 2,07; 2,03, 2,68 and 3,03 points comparing with the impairment in group E of 1,69 points. Evaluation after 2 years of treatment show a better improvement for group D (3,3 points), followed by group C (2,63 points), group B (2,43 points) and group A (2,23 points) and a greater impairment in group E (2,49 points).
Conclusion |
MCI has a better evolution in group treated with a combined therapy comparing with groups treated with monotherapy and in group E the patients present an impairment of cognitive function.
Le texte complet de cet article est disponible en PDF.Vol 27 - N° S1
P. 1 - 2012 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?